MAP2K5 and erectile dysfunction: Both miR-504 and miR-935 targeted the MEK5-ERK5-MEF2C survival pathway, inhibiting the proliferation, and promoting the apoptosis of testicular cells, resulting in a decrease in the secretion of androgens, which in turn led to a series of complications, such as reduced spermatogenesis and erectile dysfunction.